Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Predicting the Unpredictable – Taming the Impulse to Treat

Philip Seo, MD, MHS  |  Issue: January 2019  |  January 17, 2019

One of my fellows could take better care of his patients if it weren’t for the attendings getting in his way. Or so he tells me.

I can hear the howls of protest already. This statement isn’t fair—it is too broad, it doesn’t fairly depict the nuances of the situation or his point of view. First, I should point out that I know for a fact the trainee in question does not read this column, so I think I am safe, as long as none of you tell on me.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Should he find out, I would quote Erma Bombeck. If you are of a certain age, you may recall Ms. Bombeck was a nationally syndicated writer and humorist, whose columns were read by millions. She was also a wife and mother, who often wrote about her own life experiences. As you might imagine, as her children aged, they found this less amusing. One day, her children held an intervention: They informed her that if she was going to write about them, then she should be more even-handed in her depiction of them. To this, Ms. Bombeck responded with the same motherly affection and tenderness I would pass on to my own trainee, should he raise any objections: “Go out, and get your own column.”1

Honestly, the dispute comes down to a single patient, and I don’t know all the details. As a program director, I often hear bits and pieces about what irritates the fellows about various faculty members (including—more often than I like to admit—me). As in any family, however, not all arguments were meant to be voiced, and over the years, I have decided I should function less in loco parentis and more in loco avunculus—I try to lend a sympathetic ear, give some free advice when I can and slip them a $20 when Dad is being especially tough.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

This particular patient is a young woman who has centromere-positive, limited scleroderma, whose care the fellow had inherited. The fellow noted, astutely, that she had a little interstitial lung disease, and over the past year, had developed a little more.

The fellow fought to start treatment, in this case, with mycophenolate mofetil, imagining that a few pills now would save her from needing a lung transplant later. His attending demurred, arguing the lung disease was still asymptomatic, and watchful waiting was all that was needed at this time.

I certainly understand the impulse to treat—I often joke with colleagues that if I wanted to just watch sick patients become sicker, I would have become a neurologist. I am glad some physicians are attracted to this important work, but I find the management of diseases like stroke and amyotrophic lateral sclerosis to be incredibly depressing. I became an internist because I want to be able to make people better.

A true product of my training, for any patient’s complaint, I can come up with a pill. This is probably one reason why my clinic visits run long; I just can’t resist giving a patient a Medrol dose pack for his slipped disc or a steroid cream for his nummular eczema. From the legions of discharged patients who walk out with a prescription of docusate clutched in their hands, I know many of you feel the same way.

Page: 1 2 3 4 5 | Single Page
Share: 

Filed under:ConditionsOpinionRheuminationsSpeak Out Rheum Tagged with:early arthritisVery Early Rheumatoid Arthritis

Related Articles
    Lost and found

    The History of ACE Inhibitors in Scleroderma Renal Crisis

    February 16, 2021

    Scleroderma renal crisis is a true medical emergency in rheumatology, one that requires prompt diagnosis and treatment. Here, we review the historic introduction of the angiotensin-converting enzyme inhibitors in this context, and highlight management and key questions moving forward. Background Awareness of renal disease in scleroderma dates back many years. The revered physician William Osler…

    Targeted Therapy for Scleroderma Fibrosis

    October 11, 2016

    Scleroderma, or systemic sclerosis (SSc), is an autoimmune disease characterized by vasculopathy and fibrosis. Although relatively rare, with a prevalence in North America of approximately 300 per 1 million people, SSc is associated with significant morbidity and high rates of mortality.1 Patients with scleroderma have four times greater mortality than age- and sex-matched controls, with…

    Diffuse Scleroderma: A 1991 Case Through the Lens of Today

    Diffuse Scleroderma: A 1991 Case Through the Lens of Today

    February 17, 2018

    The year was 1991. It was my first Tuesday as a rheumatology fellow at the University of Pittsburgh’s Presbyterian Hospital. Navigating a maze of buildings and hallways, I delivered myself to the entrance to the scleroderma clinic. Running late and not knowing whether there was a separate entrance for staff, I clicked open the door….

    Lessons Learned from Two Scleroderma Lung Studies (Plus a Third That’s Recruiting Sites)

    August 16, 2019

    Historically, the early approach for treating interstitial lung disease (ILD) due to systemic sclerosis (SSc) involved immunosuppressant therapy, primarily with cytotoxic agents.1 Glucocorticoids in combination with another immunosuppressant agent, such as oral azathioprine or cyclophosphamide, were often used to treat patients with severe, progressive SSc-ILD.2 However, direct evidence to support this thera­peutic approach was lacking…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences